Grifols immunoglobulin treatment

grifols1 777x400 1

Grifols Starts Manufacturing Its Immunoglobulin For The Treatment Of Covid-19

Grifols announced yesterday that it has started production of hyperimmune immunoglobulin as a potential therapy for Covid-19. This makes it the first company to begin manufacturing anti-SARS-CoV-2 hyperimmune immunoglobulin, the first doses of which will be available in July. The aim is to integrate it into a clinical trial to evaluate its efficacy and subsequently begin the regulatory process for its approval.